GlassScriptPhysician profile
Gustavo Gomez
NPI 1083927297
$2,477.32
in general payments reported to CMS, 2019-2025
19 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $79.79 · 2021: $51.98 · 2022: $195 · 2023: $483 · 2024: $459 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858 · Education: $22.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.90 |
| Education | $22.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $732.72 | 2019-2025 | Stelara, Tremfya, Remicade |
| Abbvie INC. | $567.14 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.86 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $151.41 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $145.60 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $139.38 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.63 | 2022-2025 | Xifaxan |
| Novo Nordisk INC | $92.73 | 2019-2025 | Wegovy |
| Boston Scientific Corporation | $51.52 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $49.90 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $42.51 | 2025 | Iqirvo |
| Organon LLC | $41.55 | 2023-2025 | Hadlima, Renflexis |
| Genzyme Corporation | $38.83 | 2023 | |
| Allergan, INC. | $31.06 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $26.44 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $22.21 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $18.27 | 2023 | Sutab |
| Madrigal Pharmaceuticals | $16.86 | 2025 | Rezdiffra |
| Vivus LLC | $15.70 | 2025 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gustavo Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.